The production of biopharmaceuticals in plant systems

Karg, Saskia R.; Kallio, Pauli T.

doi:10.1016/j.biotechadv.2009.07.002

Cited by 121 publications

(61 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular farming, or biopharming, is a recent development using transgenic plants, including algae, for the production of high-value pharmaceuticals, including recombinant proteins (vaccines, cytokines, growth hormones) and other secondary metabolites (Daniell et al 2001;Fischer et al 2004Fischer et al , 2009Karg and Kallio 2009;Obeme et al 2011). Plants offer great potential as production platforms for important pharmaceuticals for safe and effective use by consuming edible plant tissues and seed (Hefferon 2013).…”

Section: Molecular Farmingmentioning

confidence: 98%

Next Generation Plant Biotechnology

Ahuja¹

2014

Sustainable Development and Biodiversity

View full text Add to dashboard Cite

Modern plant biotechnology began with the transfer of foreign chimeric genes into plants. Initially recombinant genes were derived from bacteria, animals and plants for gene transfer. Gene transfer was accomplished by Agrobacteriummediated or biolistic methods into the plant genome. The first wave of transgenic plants that were monitored for transgene integration and expression, the second wave transgenic plants carried economically important genes for herbicide tolerance, pest resistance, drought and salt tolerance, growth traits, and flowering control. Subsequently, a number of genetically modified crops with several useful traits have been commercialized. Although relatively stable transgene expression has been observed in a number of plant species, there were also unintended unstable events in transgenic plants. This is due to the fact that transgene integration achieved by the two traditional methods ( Agrobacterium or biolistic) of gene transfer in the plant genome is random, and one to several copies of the transgenes may be integrated at one or several locations in the genome. In order to overcome the problem of randomness of transgene integration, site-specific transgene integration strategies have been experimentally tested in plants, and offer prospects of stable gene integration and expression in transgenic plants. In order to broaden the scope of transgenic plants, biotechnologists started looking for other useful avenues for their utility. With finite reserves of fossil fuels and climate change, and growing demands for fuels, plastics, and pharmaceuticals, transgenic plants have been also explored as production platforms for these commodities. This paper is an overview of next generation transgenic plants that can serve as bioreactors or biofactories for the cost-effective production of biofuels, biopharmaceuticals, bioplastics, and as a resource for nutritional supplements to meet human demands in the future. New developments in nanobiotechnology offer prospects for improved production of crop plants.

show abstract

Section: Molecular Farmingmentioning

confidence: 98%

Next Generation Plant Biotechnology

Ahuja¹

2014

Sustainable Development and Biodiversity

View full text Add to dashboard Cite

show abstract

“…Prokaryotic cells lack the machinery to perform complex protein folding and assembly or post-translational modifications, such as N-or Oglycosylation, phosphorylation, lipid acylation, disulfide bond formation, and removal of the N-terminal methionine. These factors complicate the synthesis of complex eukaryotic proteins, which in many cases can also be toxic to the bacterial cell (Karg and Kallio, 2009).…”

Section: Expression Systems For Recombinant Protein Productionmentioning

confidence: 99%

Review Soybeans as bioreactors for biopharmaceuticals and industrial proteins

Vianna¹,

Cunha²,

Murad³

et al. 2011

Genet. Mol. Res.

View full text Add to dashboard Cite

“…Through recombinant DNA technology, different level of antigen expression for each independent line has been observed in plants (Karg and Kallio, 2009;Shih and Doran, 2009;Wilken and Nikolov, 2012). In 1990 first edible vaccine, surface protein A from Streptococcus mutans was expressed in tobacco (Curtis and Cardineray, 1990).…”

Section: Transgenic Plants For the Production Of Plant Derived Vaccinesmentioning

confidence: 99%

Transgenic plants as green factories for vaccine production

Kumar¹,

Raja²,

Wani³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Edible vaccine technology represents an alternative to fermentation based vaccine production system. Transgenic plants are used for the production of plant derived specific vaccines with native immunogenic properties stimulating both humoral and mucosal immune responses. Keeping in view the practical need of new technology for production and delivery of inexpensive vaccines, especially in developing world, plant derived edible vaccines is the best option in hand to combat infectious diseases. Plant derived vaccine is easy to administer, cost effective, readily acceptable, have increased safety, stability, versatility and efficacy. Several plant derived vaccines are under research, some are under clinical trials for commercial use. Like most biotechnology products, the IP situation for edible vaccines is complex as IP rights influence every stage of vaccine development.

show abstract

The production of biopharmaceuticals in plant systems

Cited by 121 publications

References 210 publications

Next Generation Plant Biotechnology

Next Generation Plant Biotechnology

Review Soybeans as bioreactors for biopharmaceuticals and industrial proteins

Transgenic plants as green factories for vaccine production

Contact Info

Product

Resources

About